TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03930472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Market vouchers
Description: Receiving $80 in vouchers good for fruits and vegetables or for SNAP-eligible foods at 4 out of 5 markets in late July and in August, 2019.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Market vouchers
Description: Receiving $80 in vouchers good for fruits and vegetables or for SNAP-eligible foods at 4 out of 5 markets in late July and in August, 2019.
Study: NCT01483001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cancer Stem Cells Sensitivity Assay
Description: To test in vitro sensitivity of cancer stem cells to several antineoplastic drugs in order to personalize treatment
Study: NCT03877523

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocarnit
Description: a metabolic complex
Study: NCT04219748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case Management
Description: Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team (Psychiatry, Social Work, Nursing) during 2 months. The intervention will encompass attending weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes.~This CM intervention will include referral to Hospital Clínic de Barcelona Addiction Outpatient Clinic and a personalised assessment of the medical, psychiatric and social situation of each individual by the CM team. An individualised care plan will be established and periodically reviewed by the multidisciplinary team in response to a better understanding of patient needs or to a change in patient health condition.~The intervention will offer motivational interviewing psychotherapy to enhance motivation to reduce or to quit alcohol use, in crisis intervention, coordination of care, patient education and self-management support, and assistance to navigate in the healthcare system.
Study: NCT01549613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daptomycin
Description: • Daptomycin will be given in a one-time dose of 4mg/kg in a one-time dose to be infused over 2 minutes at the initiation of patient therapy in the RDTC cellulitis protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: • Vancomycin will be given in a dose of 15mg/kg at baseline and again at 12 hours to be infused over 1 to 2 hours.
Study: NCT04475913

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DIG Axial
Description: patients received 4 axial implants and digital impression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DIG Axial
Description: patients received 4 axial implants and digital impression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DIG Tilted
Description: received two anterior axial implants and two distal tilted implants, and digital impression

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DIG Tilted
Description: received two anterior axial implants and two distal tilted implants, and digital impression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIG Axial
Description: patients received 4 axial implants and conventional impression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIG Tilted
Description: received two anterior axial implants and two distal tilted implants, and conventional impression
Study: NCT02057146

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duodenoscopy, pancreatoscopy, cholangioscopy, confocal microscopy
Description: The intervention consists of mother-baby endoscopy of the bile and/or pancreatic duct with visual inspection, confocal laser microscopy, collection of fluid for cytology, and eventually biopsy.
Study: NCT03166618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm® VOLUMA XC
Description: Juvéderm® VOLUMA XC hyaluronic acid injectable gel
Study: NCT01703260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pioglitazone placebo-matching dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Roflumilast placebo-matching dose
Study: NCT02042014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QTI571
Description: QTI571 200mg up to 400mg (depending on tolerability) taken orally, once a day.
Study: NCT04393519

Intervention type: DEVICE
Intervention: TIPS procedure
Description: Implantation of TIPS for portal hypertension
Study: NCT02097745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: a 10-25 mg stable dose given orally or parenterally throughout study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 1 g given by intravenous infusion on Days 1 and 15 of each treatment course
Study: NCT02985580

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberry

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02312323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Definitive 65 HPT contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Definitive 65 contact lenses
Study: NCT04409223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib capsules
Description: Oral KIT/PDGFRA kinase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib Capsules
Description: Oral receptor tyrosine kinase (RTK) inhibitor
Study: NCT02062060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abametapir Lotion 0.74% w/w

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Lotion
Study: NCT03911063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT sessions
Description: weekly 20-40 min CBT sessions during 8 weeks; Both the talking sessions (i.e., placebo) and CBT sessions will be performed via telemedicine either via a HIPAA secure telemedicine platform or the telephone based on the preference of the individual patient.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Talking Sessions
Description: 20-40 min talking sessions (i.e., placebo) for 8 weeks; The placebo talking sessions will be performed by an acute care and palliative care board certified, New York State licensed nurse practitioner at the NYU Dysautonomia Center who is familiar with each FD subject enrolling in the study and an expert in familial dysautonomia. The NP will focus the 20-40 minute conversation on typical medical questions and concerns that the FD patient routinely calls the Center to discuss.
Study: NCT01462760

Intervention type: DEVICE
Group type: OTHER
Intervention: Assessment with inclinometer
Description: joint assessment with inclinometer. The inclinometer used in this trial is Baseline® Bubble Inclinometer

Intervention type: DEVICE
Group type: OTHER
Intervention: Assessment with inclinometer
Description: joint assessment with inclinometer. The inclinometer used in this trial is Baseline® Bubble Inclinometer

Intervention type: DEVICE
Group type: OTHER
Intervention: Assessment with actigraph
Description: joint assessment with actigraph The actigraph used in this trial is the Motion Pod. It's an analysis and reeducation systems by biofeedback. The manufacturer is Movea.
Study: NCT02092545

Intervention type: OTHER
Group type: OTHER
Intervention: Ketogenic diet
Study: NCT02696668

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: modified FaME
Description: Group based exercise classes one hour weekly for 16 weeks. Each exercise class will have 8-10 participants and two instructors. The components of the FaME programme include specific falls management strategies, such as bone loading, gait, dynamic posture, balance, reaction and co-ordination training, functional floor activities to improve coping skills and confidence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multisensory
Description: Group based exercise classes one hour weekly for 16 weeks. Each exercise class will have 8-10 participants and two instructors.Participants will receive an initial assessment by the research physiotherapists to determine the most appropriate interventions for each participant. Interventions used will include:~1. Limits of stability training with eyes open / eyes closed~2. Self induced movement strategies with eyes open / eyes closed~3. Gaze stability exercises in sitting / standing / walking~4. Sensory integration~5. Habituation exercises
Study: NCT03139487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: 15 mg q12 hours for 3 weeks followed by 20mg q24 hours for 21 weeks
Study: NCT00119249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03283657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DiRECT
Description: DiRECT participants will meet with a medical assistant (MA) before a routinely scheduled office and formulate a preliminary treatment plan for T2D prevention. Participants will attend their scheduled physician visit, during which they may make a definitive treatment plan to initiate metformin and/or ILI.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (UC)
Description: Standard care with routine medical care.
Study: NCT02461966

Intervention type: OTHER
Group type: OTHER
Intervention: Aflatoxin
Description: Evaluation of Aflatoxin level

Intervention type: OTHER
Group type: OTHER
Intervention: Aflatoxin
Description: Evaluation of Aflatoxin level

Intervention type: OTHER
Group type: OTHER
Intervention: Aflatoxin
Description: Evaluation of Aflatoxin level
Study: NCT03972189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3101
Description: TQ-B3101 300 mg given orally in fasting conditions, twice daily in 28-day cycle.
Study: NCT03340454

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test-and-treat EHR-CHW intervention
Description: a health systems-level intervention using electronic health record (EHR)-based tools to facilitate H. pylori test-and-treat strategies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care of EHR-only intervention
Description: a community-engaged culturally and linguistically adapted CHW-led patient navigation program we are currently pilot testing for feasibility and acceptability.
Study: NCT00879905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSP990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSP990
Study: NCT00142831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacotherapies for Smoking Cessation
Description: Bupropion-SR or Identical Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacotherapies for Smoking Cessation
Description: Bupropion-SR or Identical Placebo
Study: NCT02108548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7657
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7657
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7657
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7657
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen
Description: oral
Study: NCT01937611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam
Study: NCT00409435

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pyridostigmine
Description: one 180 mg capsule per day for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one capsule per day for 3 days
Study: NCT01139957

Intervention type: PROCEDURE
Intervention: Evaluation of Cancer Risk Factors
Description: Ancillary studies

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Intervention: Study of High Risk Factors
Description: Ancillary studies
Study: NCT02311127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SecurAcath
Description: Devices secures PICC subcutaneously and remains in place during the complete dwell time of the PICC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: StatLock
Description: Device secures PICC however, device has to be changed weekly
Study: NCT02420561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: * One in-person motivational interviewing session intervention that lasts for 45-minutes~* Additional two 15-minute telephone booster sessions post in-person 45 minute sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (brochure)
Description: Participants received a brochure on alcohol and drug use risks.
Study: NCT03907748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Intervention
Description: After training, caregivers will deliver the music intervention to the person with dementia whom they care for. The music intervention will include: a) singing familiar/preferred music followed by discussions facilitated by the caregiver about any associated meanings or memories; b) movement to music (e.g. upper body and arms imitating familiar dance movements to music); c) instrument playing; and d) listening to familiar/preferred relaxing or enlivening music (dependent upon symptoms present in the moment). These methods are known to assist in emotion regulation and increase cognitive reserve (e.g. attention and perceptual-motor function).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reading Intervention
Description: After training, caregivers will deliver the reading intervention to the person with dementia whom they care for. The reading intervention will include: a) the caregiver reading aloud to the person they are caring for; b) the person with dementia reading aloud to their caregiver; and c) discussion of the text and personal responses. Strategies to engage the person with dementia and to create opportunities for meaningful dialogue will be provided, as well as guidance on selecting reading material that is accessible to the person's level of cognitive impairment.
Study: NCT04203446

Intervention type: OTHER
Intervention: Assessment of correctness of inhaling technique
Description: Assessment of correctness of inhaling technique in patients with asthma or COPD
Study: NCT01015365

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cementless one-stage surgical revision
Description: A Cementless one-stage surgical revision is to be performed for all included in the cohort.
Study: NCT02211209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volanesorsen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02821754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Flat dose of 1500 mg every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Flat dose of 1500 mg every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Flat dose of 1500 mg every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Flat dose of 1500 mg every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Flat dose of 75 mg every 4 weeks for up to 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Flat dose of 75 mg every 4 weeks for up to 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Flat dose of 75 mg every 4 weeks for up to 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Flat dose of 75 mg every 4 weeks for up to 4 doses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-arterial Catheter Chemoembolization (TACE)
Description: TACE will be performed on Day 36 (+/-96hrs).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation (RFA)
Description: RFA will be performed on Day 36 (+/-96hrs).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation will be performed on Day 36 (+/-96hrs).
Study: NCT03870269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceevra Reveal
Description: VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
Study: NCT02764814

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryopreserved amniotic membrane
Description: subjects will receive cryopreserved amniotic membrane
Study: NCT02313207

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FODMAP
Description: patients will undergo a specific FODMAP diet for a period of 2 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FODMAP
Description: patients will undergo a specific FODMAP diet for a period of 2 weeks.
Study: NCT03864757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thyroplasty implant
Description: Short-term implantation of thyroplasty implant, VOIS, and evaluation of voice quality and glottal closure. After evaluation, remove VOIS and perform medialization of vocal folds using conventional thyroplasty.
Study: NCT02203721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TECNIS Symfony Extended Range of Vision IOL, Model ZXR00

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TECNIS Monofocal IOL, Model ZCB00
Study: NCT02490371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency rTMS
Description: 1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse at 90% resting motor threshold for 10 sessions.Patients in the rTMS-ex group will receive the experimental rTMS A Magstim Rapid Stimulator (Magstim Company, Whitland, UK) equipped with an air-cooled figure-of-eight coil (each loop 70 mm in diameter) and neuro-navigation system will be used to deliver the intervention.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low frequency rTMS
Description: 1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse at 90% resting motor threshold for 10 sessions.Patients in the rTMS-ex group will receive the experimental rTMS A Magstim Rapid Stimulator (Magstim Company, Whitland, UK) equipped with an air-cooled figure-of-eight coil (each loop 70 mm in diameter) and neuro-navigation system will be used to deliver the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: structured physiotherapy upper limb training
Description: Structural Physiotherapy upper limb training for 30-minutes

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: structured physiotherapy upper limb training
Description: Structural Physiotherapy upper limb training for 30-minutes
Study: NCT02654977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metreleptin
Description: MyaLept (Recombinant-methionyl Human Leptin (r-metHuLeptin) METRELEPTIN) subcutaneous injections
Study: NCT01627574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Intervention
Description: There are two, 45-60 minutes sessions of tailored MI that occur at the enrollment of the study, and at 3 month follow-up.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Didactic Educational Intervention
Description: There are two, 45-60 minute didactic sessions designed to provide information and awareness for sexual health involving contraception and STI prevention. The first session occurs after enrollment in the study, the second at 3 month follow-up.
Study: NCT03139487

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin
Description: 200 IU/kg q24 hours for 4 weeks followed by 150 IU/kg q24 hours for 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apixaban
Description: 10 mg q12 hours for 7days followed by 5mg q12 hours for 21 weeks
Study: NCT04897165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resilience training with mobile HRV-BfB based on an e-learning approach (with digital lectures)
Description: A 4-week resilience training with a mobile HRV-BfB device. Participants received access to three online lectures at the start of the first, third, and forth training week (each lasting 60 minutes) to receive a theoretical base on resilience and to learn how to exercise with the HRV-BfB device. Participants were asked to exercise three times a day for 5 minutes in their occupational and leisure time with the HRV-BfB device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resilience training with mobile HRV-BfB based on a blended learning approach (with live lectures)
Description: A 4-week resilience training with a mobile HRV-BfB device. Participants attended three live lectures at the start of the first, third, and forth training week (each lasting 90 minutes) to receive a theoretical base on resilience and to learn how to exercise with the HRV-BfB device. Participants were asked to exercise three times a day for 5 minutes in their occupational and leisure time with the HRV-BfB device.
Study: NCT01331473

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid Artery Stenting with Proximal Protection
Description: Carotid artery angioplasty and stenting with proximal embolic protection provided by the GORE Neuro Protection System

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid Artery Stenting without Protection
Description: Carotid artery angioplasty and stenting without cerebral embolic protection
Study: NCT03813654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8-h Afternoon-Evening Sleep
Description: 8 consecutive hours time in bed during the afternoon/evening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8-h Free Sleep
Description: 8 consecutive hours time in bed at any time.
Study: NCT03398005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CaPre
Description: 4 x 1 g capsules administered orally once a day for 26 weeks
Study: NCT04411901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitaminD3)
Description: Theraputic vitamin D3 for CF and non CF bronchiectasis children
Study: NCT02651961

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exchange of total hip or knee arthroplasty in two time
Description: Removal of the index implants in first time, extensive debridement, reimplantation of a new prosthesis in seconde time